Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,984 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intracerebroventricular 2-hydroxypropyl-γ-cyclodextrin alleviates hepatic manifestations without distributing to the liver in a murine model of Niemann-Pick disease type C.
Yamada Y, Ishitsuka Y, Fukaura-Nishizawa M, Kawata T, Ishii A, Shirakawa A, Sakai T, Tanaka M, Kondo Y, Takeo T, Nakagata N, Motoyama K, Higashi T, Arima H, Seki T, Kurauchi Y, Katsuki H, Higaki K, Ikeda R, Matsuo M, Era T, Irie T. Yamada Y, et al. Life Sci. 2024 Aug 1;350:122776. doi: 10.1016/j.lfs.2024.122776. Epub 2024 Jun 7. Life Sci. 2024. PMID: 38852794
Efficacy of 2-Hydroxypropyl-β-cyclodextrin in Niemann-Pick Disease Type C Model Mice and Its Pharmacokinetic Analysis in a Patient with the Disease.
Tanaka Y, Yamada Y, Ishitsuka Y, Matsuo M, Shiraishi K, Wada K, Uchio Y, Kondo Y, Takeo T, Nakagata N, Higashi T, Motoyama K, Arima H, Mochinaga S, Higaki K, Ohno K, Irie T. Tanaka Y, et al. Among authors: yamada y. Biol Pharm Bull. 2015;38(6):844-51. doi: 10.1248/bpb.b14-00726. Biol Pharm Bull. 2015. PMID: 26027824 Free article.
Influence of Npc1 genotype on the toxicity of hydroxypropyl-β-cyclodextrin, a potentially therapeutic agent, in Niemann-Pick Type C disease models.
Tanaka Y, Ishitsuka Y, Yamada Y, Kondo Y, Takeo T, Nakagata N, Higashi T, Motoyama K, Arima H, Matsuo M, Higaki K, Ohno K, Irie T. Tanaka Y, et al. Among authors: yamada y. Mol Genet Metab Rep. 2014 Jan 11;1:19-30. doi: 10.1016/j.ymgmr.2013.12.003. eCollection 2014. Mol Genet Metab Rep. 2014. PMID: 27896072 Free PMC article.
In Vitro and In Vivo Evaluation of 6-O-α-Maltosyl-β-Cyclodextrin as a Potential Therapeutic Agent Against Niemann-Pick Disease Type C.
Yasmin N, Ishitsuka Y, Fukaura M, Yamada Y, Nakahara S, Ishii A, Kondo Y, Takeo T, Nakagata N, Motoyama K, Higashi T, Okada Y, Nishikawa J, Ichikawa A, Iohara D, Hirayama F, Higaki K, Ohno K, Matsuo M, Irie T. Yasmin N, et al. Among authors: yamada y. Int J Mol Sci. 2019 Mar 6;20(5):1152. doi: 10.3390/ijms20051152. Int J Mol Sci. 2019. PMID: 30845767 Free PMC article.
Intracerebroventricular Treatment with 2-Hydroxypropyl-β-Cyclodextrin Decreased Cerebellar and Hepatic Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Expression in Niemann-Pick Disease Type C Model Mice.
Fukaura M, Ishitsuka Y, Shirakawa S, Ushihama N, Yamada Y, Kondo Y, Takeo T, Nakagata N, Motoyama K, Higashi T, Arima H, Kurauchi Y, Seki T, Katsuki H, Higaki K, Matsuo M, Irie T. Fukaura M, et al. Among authors: yamada y. Int J Mol Sci. 2021 Jan 5;22(1):452. doi: 10.3390/ijms22010452. Int J Mol Sci. 2021. PMID: 33466390 Free PMC article.
Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins increases safety margin in treatment of Niemann-Pick disease type C.
Yamada Y, Ishitsuka Y, Kondo Y, Nakahara S, Nishiyama A, Takeo T, Nakagata N, Motoyama K, Higashi T, Arima H, Kamei S, Shuto T, Kai H, Hayashino Y, Sugita M, Kikuchi T, Hirata F, Miwa T, Takeda H, Orita Y, Seki T, Ohta T, Kurauchi Y, Katsuki H, Matsuo M, Higaki K, Ohno K, Matsumoto S, Era T, Irie T. Yamada Y, et al. Br J Pharmacol. 2021 Jul;178(13):2727-2746. doi: 10.1111/bph.15464. Epub 2021 May 12. Br J Pharmacol. 2021. PMID: 33782944 Free article.
Fine-tuned cholesterol solubilizer, mono-6-O-α-D-maltosyl-γ-cyclodextrin, ameliorates experimental Niemann-Pick disease type C without hearing loss.
Yamada Y, Miwa T, Nakashima M, Shirakawa A, Ishii A, Namba N, Kondo Y, Takeo T, Nakagata N, Motoyama K, Higashi T, Arima H, Kurauchi Y, Seki T, Katsuki H, Okada Y, Ichikawa A, Higaki K, Hayashi K, Minami K, Yoshikawa N, Ikeda R, Ishikawa Y, Kajii T, Tachii K, Takeda H, Orita Y, Matsuo M, Irie T, Ishitsuka Y. Yamada Y, et al. Biomed Pharmacother. 2022 Nov;155:113698. doi: 10.1016/j.biopha.2022.113698. Epub 2022 Sep 16. Biomed Pharmacother. 2022. PMID: 36116252 Free article.
Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann-Pick disease type C treatment.
Yamada Y, Fukaura-Nishizawa M, Nishiyama A, Ishii A, Kawata T, Shirakawa A, Tanaka M, Kondo Y, Takeo T, Nakagata N, Miwa T, Takeda H, Orita Y, Motoyama K, Higashi T, Arima H, Seki T, Kurauchi Y, Katsuki H, Higaki K, Minami K, Yoshikawa N, Ikeda R, Matsuo M, Irie T, Ishitsuka Y. Yamada Y, et al. Clin Transl Med. 2023 Aug;13(8):e1350. doi: 10.1002/ctm2.1350. Clin Transl Med. 2023. PMID: 37620691 Free PMC article.
In vivo Efficacy and Safety Evaluation of Lactosyl-β-cyclodextrin as a Therapeutic Agent for Hepatomegaly in Niemann-Pick Type C Disease.
Maeda Y, Motoyama K, Nishiyama R, Higashi T, Onodera R, Nakamura H, Takeo T, Nakagata N, Yamada Y, Ishitsuka Y, Kondo Y, Irie T, Era T, Arima H. Maeda Y, et al. Among authors: yamada y. Nanomaterials (Basel). 2019 May 25;9(5):802. doi: 10.3390/nano9050802. Nanomaterials (Basel). 2019. PMID: 31130658 Free PMC article.
9,984 results